The management of locally advanced lung cancer increasingly relies on multidisciplinary collaboration. Advances in neoadjuvant and perioperative chemoimmunotherapy have significantly improved outcomes for patients with resectable non-small cell lung cancer.
This combined immunotherapy track and lung cancer track brings together leading experts to discuss recent, cutting-edge trials and strategies in treating both locally advanced and metastatic non-small cell lung cancer (NSCLC). Dr.
This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a strategic dialogue with the ASTRO CEO and a radiation oncology practice overview.
This session highlights six of the most clinically relevant abstracts within the Lung Cancers/Thoracic Malignancies track of the 2024 ASTRO Annual Meeting scientific program.
The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.
Patients with interstitial lung disease (ILD), especially those with pulmonary fibrosis, are at increased risk of developing lung cancer. Management of lung cancer in patients with ILD is particularly challenging.
The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.
The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.
This activity focuses entirely on issues related to the Organs at Risk (OAR) in the setting of thoracic radiation. Discussion centers on protecting the OARs and managing acute and late toxicities. Each speaker focuses on a different clinical situation.